Table 1.
Patient Demographics: Full cohort (N = 528), NCCN AS-Ineligible (N = 312), and NCCN AS Eligible (N = 216).
| Full cohort (N = 528) | Non-NCCN (N = 312) | * NCCN pts (N = 216) | ||||
|---|---|---|---|---|---|---|
| Factor | Mean ± SE | Mean ± SE | Mean ± SE | |||
| Age | 63y ± 0.3y | 63y ± 0.4y | 62y ± 0.6y | |||
| Pre-Bx Serum PSA | 7.0 ± 0.4 | 8.2 ± 0.7 | 5.3 ± 0.2 | |||
| Factor | N | (%) | N | (%) | N | (%) |
| Serum PSA | ||||||
| <10 | 456 | (86.4) | 243 | (77.9) | 213 | (98.6) |
| 10–20 | 58 | (11.0) | 56 | (17.9) | 2 | (0.5) |
| > 20 | 14 | (2.6) | 13 | (4.2) | 1 | (0.9) |
| Gleason Sum | ||||||
| 6 | 231 | (43.7) | 25 | (8.0) | 206 | (95.4) |
| 7 | 255 | (48.3) | 245 | (78.5) | 10 | (4.6) |
| 8–9 | 42 | (8.0) | 42 | (13.5) | 0 | (0.0) |
| Ethnicity | ||||||
| African-American | 23 | (4.4) | 14 | (4.5) | 9 | (4.2) |
| Asian | 29 | (5.5) | 17 | (5.4) | 12 | (5.5) |
| Caucasian | 470 | (89.0) | 279 | (89.4) | 191 | (88.4) |
| Native American | 1 | (0.2) | 0 | (0.0) | 1 | (0.5) |
| Other | 5 | (0.9) | 2 | (0.6) | 3 | (1.4) |
| T-stage | ||||||
| T1a | 2 | (0.4) | 1 | (0.3) | 1 | (0.4) |
| T1c | 425 | (80.5) | 241 | (77.2) | 184 | (85.2) |
| T2a | 77 | (14.6) | 46 | (14.7) | 31 | (14.4) |
| T1b or Other T2 | 24 | (4.5) | 24 | (7.7) | 0 | (0.0) |
| Upstaged | 97 | (18.4) | 82 | (26.3) | 15 | (6.9) |
| Upgraded | 121 | (23.0) | 31 | (9.9) | 90 | (42.1) |
*
NCCN AS eligibility criteria are defined as follows. Low risk: T1-T2a, Gleason ≤ 6, PSA <10, OR
Intermediate risk: for < 10 years of life expectancy, T2b-T2c or Gleason 7 or PSA 10–20. NCCN recommends AS for very low risk patients; these patients are also eligible for AS and are contained in the low risk group as defined by NCCN.